| 6.38 -0.21 (-3.19%) | 11-20 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | ||||
| Targets | 6-month : | 8.23 | 1-year : | 9.39 |
| Resists | First : | 7.05 | Second : | 8.03 |
| Pivot price | 7.13 |
|||
| Supports | First : | 5.44 | Second : | 4.53 |
| MAs | MA(5) : | 6.86 |
MA(20) : | 6.82 |
| MA(100) : | 6.69 |
MA(250) : | 6.79 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 31.5 |
D(3) : | 46.4 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 8.94 | Low : | 4.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PROF ] has closed above bottom band by 1.3%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.69 - 6.76 | 6.76 - 6.8 |
| Low: | 6.16 - 6.24 | 6.24 - 6.29 |
| Close: | 6.29 - 6.42 | 6.42 - 6.5 |
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
Sat, 21 Nov 2026
Is Profound Medical (NASDAQ:PROF) Worth A Closer Look Now? - Kalkine Media
Wed, 11 Nov 2026
Profound Medical (NasdaqCM:PROF) Stock Forecast & Analyst Predictions - Simply Wall St
Fri, 06 Nov 2026
What Profound Medical (PROF) Said on Its Q3 Earnings Call - Yahoo Finance
Mon, 02 Nov 2026
Profound Medical expands U.S. sales network through Cook Medical partnership (PROF:NASDAQ) - Seeking Alpha
Fri, 09 Oct 2026
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? - Yahoo Finance
Fri, 09 Oct 2026
Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 37 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 45.4 (%) |
| Shares Short | 1,560 (K) |
| Shares Short P.Month | 1,570 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.83 |
| Profit Margin | -171.6 % |
| Operating Margin | -445.7 % |
| Return on Assets (ttm) | -39.5 % |
| Return on Equity (ttm) | -73.6 % |
| Qtrly Rev. Growth | 12.3 % |
| Gross Profit (p.s.) | 0.37 |
| Sales Per Share | 0.52 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -6.45 |
| PEG Ratio | 0 |
| Price to Book value | 3.48 |
| Price to Sales | 12.24 |
| Price to Cash Flow | -6.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |